Driven by the increasing need to demonstrate safety and efficacy in IO therapies as quickly as possible, our first Roundtable event explored how CD8 ImmunoPET could potentially provide a solution to assist in providing qualitative assessments and quantitative measurements in IO clinical trials.
The content within the recording and the transcript of the Roundtable on how “imaging may improve decision making in IO clinical trials” that took place on December 5th 2021, has been made available for informational and educational purposes only. This information is only available to pharmaceutical and biotech personnel working on projects related to IO clinical trials.
The efficacy and safety of ImaginAb’s investigational CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) discussed during the Roundtable event have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation
Please find below the full recording of our engaging discussion with our expert panel: